Statistics for Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis
Total visits
| views | |
|---|---|
| Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis | 5 |
Total visits per month
| views | |
|---|---|
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 1 |
| April 2025 | 0 |
File Visits
| views | |
|---|---|
| Nikolaou2021Belantamab-CCBYNCND.pdf | 35 |
| java.util.UUID:3ab15dde-6b5f-4dfc-9134-62e730832bd8 | 33 |
| java.util.UUID:9202b65e-5efc-40d0-9bac-7d386b82481e | 15 |
| java.util.UUID:79fb7fa3-d74f-43f9-a11b-c9955ccd7674 | 6 |
Top country views
| views | |
|---|---|
| United States | 4 |
| India | 1 |
Top city views
| views | |
|---|---|
| Bloomington | 2 |
| Columbus | 1 |
| Franklin | 1 |
| Pune | 1 |